IMMUTEP LIMITED

4.08%

23.5¢

Market Cap $344.9M

Healthcare Biotechnology

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Latest Threads

Tag

Subject

IMM

Media

6 7 8

16:53

473

229K

16:53

Last post theoc

473

229K

IMM

Ann: Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed

04/09/25

9.2K

04/09/25

Last post GreenWave

9.2K

IMM Algorithmic Trading

Under New Management

03/09/25

115

65K

03/09/25

Last post Bylosellhi

115

65K

IMM

Ann: TACTI-004 trial in progress poster to be presented at WCLC

30/08/25

1.0K

30/08/25

Last post tankhexman

1.0K

IMM Biotech

Stop hedge fund manipulation

29/08/25

4.1K

29/08/25

Last post Hslm

4.1K

IMM

Ann: Appendix 4E & 2025 Full Year Statutory Accounts

29/08/25

307

29/08/25

Last post

ASX News

307

IMM

Ann: FDA feedback received for head & neck cancer in CPS below 1

08/08/25

8.6K

08/08/25

Last post troutfisho

8.6K

IMM

Ann: Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial

31/07/25

13K

31/07/25

Last post tankhexman

13K

See All Discussions

Timeline

Appendix 4E & 2025 Full Year Statutory Accounts
29 Aug 09:30	Share

FDA feedback received for head & neck cancer in CPS below 1
05 Aug 09:26	Share

Immutep Quarterly Activities Report and Appendix 4C
30 Jul 08:25	Share

TACTI-004 trial in progress poster to be presented at WCLC
29 Jul 08:21	Share

Abstracts Accepted for Presentation at ESMO Congress 2025
28 Jul 09:27	Share

Ceasing to be a substantial holder
25 Jul 08:16	Share

Ceasing to be a substantial holder
23 Jul 17:40	Share

Application for quotation of securities - IMM
18 Jul 12:10	Share

Application for quotation of securities - IMM
18 Jul 12:09	Share

Change in substantial holding
17 Jul 08:19	Share

Change in substantial holding
30 Jun 16:39	Share

Update on Phase I Study of IMP761 for Autoimmune Diseases
23 Jun 08:33	Share

Immutep Corporate Presentation
02 Jun 08:21	Share

Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial
26 May 08:22	Share

High Response Rates achieved in Lung Cancer in INSIGHT-003
15 May 08:16	Share

Excellent Overall Survival in Head & Neck Cancer Patients
05 May 08:22	Share

Change in substantial holding
01 May 16:36	Share

Immutep Quarterly Activities Report and Appendix 4C
29 Apr 09:02	Share

Immutep Investor Update
23 Apr 10:24	Share

Change in substantial holding
11 Apr 08:20	Share

Change of Director's Interest Notice - M Voigt
08 Apr 15:32	Share

Change of Director's Interest Notice F Triebel
08 Apr 15:31	Share

Application for quotation of securities - IMM
03 Apr 14:31	Share

Immutep to Participate in Upcoming Investor Conferences
02 Apr 08:31	Share

First patient dosed in phase 3 TACTI-004 lung cancer trial
25 Mar 08:38	Share

TACTI-004 trial in progress poster to be presented at ELCC
20 Mar 10:29	Share

Half Yearly Report and Accounts
26 Feb 18:58	Share

Notification of cessation of securities - IMM
06 Feb 18:03	Share

Immutep Corporate Presentation
05 Feb 11:37	Share

Immutep Quarterly Activities Report and Appendix 4C
31 Jan 08:27	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 23.5¢		Change -0.010(4.08%)		Mkt cap ! $344.9M

Open	High	Low	Value	Volume
24.0¢	24.3¢	23.5¢	$408.8K	1.709M

Buyers (Bids)

No.	Vol.	Price($)
14	1472949	23.5¢

Sellers (Offers)

Price($)	Vol.	No.
24.0¢	142000	3

View Market Depth

No.	Vol.	Price($)
14	1472949	0.235
14	297206	0.230
19	485644	0.225
15	548932	0.220
6	81358	0.215

Price($)	Vol.	No.
0.240	142000	3
0.245	216840	4
0.250	183468	6
0.255	140000	4
0.260	282631	9

Last trade - 16.10pm 05/09/2025 (20 minute delay)


Last 23.5¢		Change -0.010 ( 4.08 %)
Open	High	Low	Volume
24.0¢	24.3¢	23.5¢	668944
Last updated 15.55pm 05/09/2025 ?

IMM (ASX) Chart

IMMUTEP LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Immutep (ASX:IMM) enrols 50pc of patients for TACTI-003 trial

04 Jan 2023 08:19 (AEDT)

Latest Articles

Immutep notches upward on first lung cancer patient dosing

Immutep Ltd has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial in its final stage of clinical study.

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has seen no adverse effects.

Immutep snaffles A$3.6M from French government for R&D

Immutep Ltd has received a R&D award of around A$3.6 million to develop two of its immunotherapy candidates

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News